An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Enrolling by invitation
Astex Pharmaceuticals, Inc.
Phase 2
2019-09-30
Extension study for subjects who participated in a previous Astex-sponsored clinical study of
ASTX727 (including, but not limited to ASTX727-01, ASTX727-02, ASTX727-04).
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Recruiting
National Cancer Institute (NCI)
Phase 2
2020-07-06
This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727
in treating patients with conventional chondrosarcoma that cannot be removed by surgery
(unresectable) and has spread to other places in the body (metastatic). Belinostat may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Chemotherapy drugs, such as guadecitabine and ASTX727, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving belinostat in combination with guadecitabine or ASTX727
may lower the chance of unresectable and metastatic chondrosarcoma growing or spreading.
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recruiting
Astex Pharmaceuticals, Inc.
Phase 1/Phase 2
2021-01-19
This phase I/II trial studies the side effects and best dose of venetoclax in combination
with cedazuridine and decitabine (ASTX727) in treating patients with high risk
myelodysplastic syndrome or chronic myelomonocytic leukemia who have not received prior
treatment (treatment-naive). Chemotherapy drugs, such as venetoclax, cedazuridine, and
decitabine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
